NRF2 and cancer: the good, the bad and the importance of context
Open accessThe DOI matches its Crossref record; 119 of the 120 references it cites were found in a registry or an index.
Abstract
Many studies of chemopreventive drugs have suggested that their beneficial effects on suppression of carcinogenesis and many other chronic diseases are mediated through activation of the transcription factor NFE2-related factor 2 (NRF2). More recently, genetic analyses of human tumours have indicated that NRF2 may conversely be oncogenic and cause resistance to chemotherapy. It is therefore controversial whether the activation, or alternatively the inhibition, of NRF2 is a useful strategy for the prevention or treatment of cancer. This Opinion article aims to rationalize these conflicting perspectives by critiquing the context dependence of NRF2 functions and the experimental methods behind these conflicting data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NRF2 is activated and overexpressed in cancer to promote cancer cell survival; the cellular antioxidant system is largely regulated by NRF2 and its associated genes.30”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [30]
In the citing paper
“Furthermore, increased ROS levels facilitate the activation of HIF1α and NRF2 transcription factors, thus promoting transcriptional programs that further contribute to tumorigenesis (Bertout et al., 2008; Sporn and Liby, 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Sporn and Liby, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Niture, S. K., Jain, A. K., & Jaiswal, A. K. (2009) · Journal of Cell Science · doi:10.1242/jcs.058537 · Cited by 192
RetractedPhosphorylation and Dephosphorylation of Tyrosine 141 Regulate Stability and Degradation of INrf2
Jain, A. K., Mahajan, S., & Jaiswal, A. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709854200 · Cited by 49
RetractedHsp90 Interaction with INrf2(Keap1) Mediates Stress-induced Nrf2 Activation
Niture, S. K., & Jaiswal, A. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175802 · Cited by 41
RetractedTargeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,677
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
Cited by
Items 601–700 of 1,000
Metabolic, autophagic, and mitophagic activities in cancer initiation and progression
Hjelmeland, A. B., & Zhang, J. (2016) · Biomedical Journal · doi:10.1016/j.bj.2015.10.002 · Cited by 26
“Thus, it may be difficult to make broad conclusions regarding the use of antioxidants for cancer therapy in the context of the diverse initiation and progression mechanisms of the disease [17,55,56,62].”
BackgroundJang, Y., Choo, H., Lee, M. J., Han, J., Kim, S., Ju, X., Cui, J., Lee, Y. L., Ryu, M. J., Oh, E., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143409 · Cited by 27
“Activation of NRF2 has been reported in several types of cancer cells [41].”
The tumor suppression theory of aging
Wolf, A. M. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111583 · Cited by 30
Autophagy and pluripotency: self-eating your way to eternal youth
Xu, Y., & Yang, X. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.04.001 · Cited by 25
Léon-Letelier, R. A., Sater, A. H. A., Chen, Y., Park, S., Wu, R., Irajizad, E., Dennison, J. B., Katayama, H., Vykoukal, J. V., Hanash, S., et al. (2023) · Cancers · doi:10.3390/cancers15030834 · Cited by 26
“Increasing evidence supports a key role of NRF2 in reprogramming cancer cell metabolism, with several NRF2 target genes involved in the regulation of glycolysis, pentose phosphate pathway, fatty acid metabolism, glutamine metabolism, and glutathione metabolism [2,20,21].”
BackgroundMcMahon, M. J., Campbell, K. H., MacLeod, A. K., McLaughlin, L. A., Henderson, C. J., & Wolf, C. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114055 · Cited by 24
“While transient activation of NRF2 in normal cells is desirable, persistent activation of NRF2 is deleterious [6].”
BackgroundMutationAligner: a resource of recurrent mutation hotspots in protein domains in cancer
Gauthier, N. P., Reznik, E., Gao, J., Sümer, S. O., Schultz, N. D., Sander, C., & Miller, M. L. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1132 · Cited by 24
“KEAP1 is cysteine-rich, and modification of cysteine residues due to oxidative stress can induce a conformational change in KEAP1, leading to the nuclear translocation of NRF2 and up-regulation of anti-oxidant stress response genes (15).”
BackgroundAutocrine and Paracrine Regulation of Keratinocyte Proliferation through a Novel Nrf2–IL-36γ Pathway
Kurinna, S. M., Muzumdar, S., Köhler, U. A., Kockmann, T., Keller, U. A. D., Schäfer, M., & Werner, S. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501447 · Cited by 24
“In response to electrophiles and under certain circumstances in response to ROS directly, the Nrf2–Keap1 interaction is weakened, leading to stabilization of Nrf2 and translocation of newly synthesized Nrf2 protein to the nucleus (2).”
BackgroundInfluentialPeroxiredoxin I is important for cancer-cell survival in Ras-induced hepatic tumorigenesis
Han, B., Shin, H., Bak, I. S., Bak, Y., Jeong, Y., Kwon, T., Park, Y., Sun, H., Kim, C., & Yu, D. (2016) · Oncotarget · doi:10.18632/oncotarget.11172 · Cited by 24
Kwon, Y. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e00753 · Cited by 24
Yamaguchi, Y., Kamai, T., Higashi, S., Murakami, S., Arai, K., Shirataki, H., & Yoshida, K. (2019) · BMC Cancer · doi:10.1186/s12885-019-6347-0 · Cited by 25
Lohakul, J., Chaiprasongsuk, A., Jeayeng, S., Saelim, M., Muanjumpon, P., Thanachaiphiwat, S., Tripatara, P., Soontrapa, K., Lumlerdkij, N., Akarasereenont, P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.649820 · Cited by 32
“Attempts have been made to develop Nrf2 activators as chemopreventive strategies including photoprotective agents for the prevention of photocarcinogenesis, although it should be taken into consideration that Nrf2 can be the double-edged sword in human cells and a harmful aspect of Nrf2 in the biology of skin cancer h…”
BackgroundIron accumulation and lipid peroxidation: implication of ferroptosis in hepatocellular carcinoma
Li, X., Meng, F., Wang, H., Sun, L., Chang, S., Li, G., & Chen, F. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1319969 · Cited by 29
“NRF 2 transcriptionally induces the expression of several antioxidant defense proteins involved in iron and ROS metabolism, such as SOD1, GPX4, glutathione synthetase (GCL and GSS), HO-1, and FTH 1 (86 – 88).”
BackgroundRetracted: p62 as a therapeutic target for inhibition of autophagy in prostate cancer
Wang, L., Kim, D., Wise, J. T. F., Shi, X., Zhang, Z., & DiPaola, R. S. (2018) · The Prostate · doi:10.1002/pros.23483 · Cited by 26
RetractedPoornima, P., Kankia, I. H., Langdon, S. P., & Deeni, Y. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.57 · Cited by 30
“Other reasons for NRF2 over-expression include epigenetic and post-translational modification, increased disruptor proteins, proto-oncogenes etc.([127-130]).”
BackgroundMolecular Mechanisms of Nickel-Induced Carcinogenesis
Son, Y. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666191125112728 · Cited by 26
Wang, Q., Xu, L., Wang, G., Chen, L., Li, C., Jiang, X., Gao, H., Yang, B., & Tian, W. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241241 · Cited by 26
“KEAP1 can sequester NRF2 in the cytoplasm and lead to ubiquitination of CUL3 E3 ligase and subsequent degradation by the proteasome [3,4].”
BackgroundThe impact of mitochondria on cancer treatment resistance
van der Merwe, M., van Niekerk, G., Fourie, C., du Plessis, M., & Engelbrecht, A. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00623-y · Cited by 26
“Nrf2 exerts cytoprotective effects in both non-cancerous and cancerous cells, implying that it prevents cell transformation, but that once a cell has become cancerous, it confers a survival advantage by upregulating detoxification processes [45].”
BackgroundGotö, Y., Koyasu, S., Kobayashi, M., & Harada, H. (2017) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2017.07.007 · Cited by 26
PGC-1α as a Biomarker of Physical Activity-Protective Effect on Colorectal Cancer
Teixeira, F. D. S., Alonso-Molero, J., Ayán, C., Vilorio-Marqués, L., Molina, A. J., González-Donquiles, C., Dávila‐Batista, V., Fernández‐Villa, T., de Paz, J. A., & Martín, V. (2018) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-17-0329 · Cited by 26
Activation of NRF2 by topical apocarotenoid treatment mitigates radiation-induced dermatitis
Schmidlin, C. J., de la Vega, M. R., Perer, J., Zhang, D. D., & Wondrak, G. T. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101714 · Cited by 26
Resheq, Y. J., Li, K., Ward, S., Wilhelm, A., Garg, A., Curbishley, S. M., Blahova, M., Zimmermann, H. W., Jitschin, R., Mougiakakos, D., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401046 · Cited by 23
Binding of Disordered Peptides to Kelch: Insights from Enhanced Sampling Simulations
Do, T. N., Choy, W., & Karttunen, M. (2015) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.5b00868 · Cited by 24
Spotlight on ROS and β 3-Adrenoreceptors Fighting in Cancer Cells
Calvani, M., Subbiani, A., Vignoli, M., & Favre, C. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/6346529 · Cited by 28
Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in non-small cell lung cancer
Zeng, Z., Wang, Z., Li, Y., Ye, D., Zeng, J., Hu, J., Chen, P.-F., Xiao, J., Zou, J., & Li, Z. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117325 · Cited by 22
LTBP2 Knockdown Promotes Ferroptosis in Gastric Cancer Cells through p62‐Keap1‐Nrf2 Pathway
Wang, T., Zhou, Z., Wang, C., Qin, Y., Wu, L., Hu, B.-L., Jin, Q., Wei, W., & Huang, M. (2022) · BioMed Research International · doi:10.1155/2022/6532253 · Cited by 23
“When ROS accumulation in cells is excessive, the endogenous Nrf2 signaling pathway can be activated [21].”
Maki, Y., Fujimoto, J., Lang, W., Li, X., Behrens, C., Wistuba, I. I., & Kadara, H. N. (2015) · Scientific Reports · doi:10.1038/srep13846 · Cited by 24
Son, Y., Pratheeshkumar, P., Divya, S. P., Zhang, Z., & Shi, X. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.773986 · Cited by 24
“Furthermore, high Nrf2 levels in cancer cells correlate with chemoresistance (34,39-42).”
BackgroundRetractedWang, T., Hu, P., Li, B., Zhang, J., Cheng, Y., & Liang, Y.-M. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s122803 · Cited by 22
“Moreover, Nrf2 could also regulate many genes except for the classic cytoprotective ones, especially in terms of cell differentiation and proliferation.(12) Nrf2 signaling pathway is considered the most crucial pathway in the cell for the protection of cells against oxidative stress.”
RetractedZheng, K., Zhang, Q., Sheng, Z.-Q., Li, Y., & Lu, H.-H. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495711 · Cited by 23
Nazmeen, A., Chen, G., Ghosh, T. K., & Maiti, S. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1153-y · Cited by 21
Pesaraklou, A., & Matin, M. M. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0104 · Cited by 22
Yun, S., Kim, Y. S., & Hur, D. Y. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.02.009 · Cited by 21
The Effects of Dietary Supplements that Overactivate the Nrf2/ARE System
Smith, R. E. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190517113533 · Cited by 22
Ochratoxin A Sequentially Activates Autophagy and the Ubiquitin-Proteasome System
Akpinar, H. A., Kahraman, H., & Yaman, İ. (2019) · Toxins · doi:10.3390/toxins11110615 · Cited by 24
“We observed that MCL1, KEAP1, and IKBα diminished at a steeper rate when cells were exposed to CHX and OTA compared to the CHX alone condition, supporting the notion that OTA promotes faster protein degradation (Figure S5a).”
BackgroundInfluentialZeng, Y., Guo, Z., Hu, Z., Liu, M., Chen, Y., Chen, S., Peng, B., Zhang, P., Wu, Z. H., Luo, H., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110029 · Cited by 23
Obtusaquinone: A Cysteine-Modifying Compound That Targets Keap1 for Degradation
Badr, C. E., da Hora, C. C., Kirov, A. B., Tabet, E. I., Amante, R. J., Maksoud, S., Nibbs, A. E., Fitzsimons, E., Boukhali, M., Chen, J. W., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00104 · Cited by 22
Krejbich, P., & Birringer, M. (2022) · Antioxidants · doi:10.3390/antiox11112149 · Cited by 27
Bae, E. S., Byun, W. S., Ock, C. W., Kim, W. K., Park, H. J., & Lee, S. K. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114039 · Cited by 25
Importance of lactate dehydrogenase (LDH) and monocarboxylate transporters (MCTs) in cancer cells
Hatami, H., Sajedi, A., Mir, S. M., & Memar, M. Y. (2022) · Health Science Reports · doi:10.1002/hsr2.996 · Cited by 22
“Other effects of enhancement of ROS are facilitating the activation of hypoxia‐inducible factor 1‐alpha (HIF1‐α) and nuclear factor erythroid 2‐related factor 2 (NRF2).(40,41) In hypoxia conditions, induced overexpression of mitochondrial SHMT2 (serine hydroxyl methyl transferase 2) protects cells against the toxic ef…”
BackgroundLiu, D., Hu, Z., Lu, J., & Yi, C. (2024) · Antioxidants · doi:10.3390/antiox13070791 · Cited by 26
“Nuclear factor erythroid 2-related factor 2 (Nrf2) regulates oxidative reactions and stabilizes the intracellular environment [183].”
BackgroundMolecular Pathogenesis of Liver Injury in Hereditary Tyrosinemia 1
Tanguay, R. M., Angileri, F., & Vogel, A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_4 · Cited by 22
Chatterjee, N., & Bohmann, D. (2018) · BioEssays · doi:10.1002/bies.201800007 · Cited by 22
Zhang, J., Jiao, K., Liu, J., & Xia, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.9382 · Cited by 24
“The major challenge in improving the prognosis of lung adenocarcinoma patients is the drug resistance to cisplatin, in which the Kelch-like ECH-associated protein 1 (Keap1)/nuclear factor, erythroid 2 like 2 (Nrf2)/antioxidant response element (ARE) signaling pathway has a critical role (1-3).”
Kretschmer, N., Deutsch, A. J. A., Durchschein, C., Rinner, B., Stallinger, A., Higareda‐Almaraz, J. C., Scheideler, M., Lohberger, B., & Bauer, R. (2018) · Molecules · doi:10.3390/molecules23112823 · Cited by 23
“as a consequence, enhanced autophagic flux [20,21,27].”
BackgroundInfluentialXu, W.-Y., Hu, Q.-S., Qin, Y., Zhang, B., Liu, W., Ni, Q., Xu, J., & Yu, X. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i43.4893 · Cited by 21
Clementino, M., Kim, D., & Zhang, Z. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz032 · Cited by 22
Nrf2 in Neoplastic and Non-Neoplastic Liver Diseases
Orrù, C., Giordano, S., & Columbano, A. (2020) · Cancers · doi:10.3390/cancers12102932 · Cited by 22
“As a consequence of the role played by Nrf2 in antioxidative defense, Nrf2 activation should be pursued for preventing, not only chronic liver diseases, but also cancer development, especially at early stages of hepatocarcinogenesis [13].”
BackgroundQu, H., Barrett, H., Wang, B., Han, J., Wang, F., Gong, W., Wu, J., Wang, W., & Yu, G. (2020) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2020.124871 · Cited by 21
Moreira, A. J., Rodrigues, G., Bona, S., Fratta, L. X. S., Weber, G. R., Picada, J. N., dos Santos, J. L., Cerski, C. T. S., Marroni, C. A., & Marroni, N. P. (2016) · PROTOPLASMA · doi:10.1007/s00709-016-1000-0 · Cited by 21
“In cancer, Nrf2 behaves in a complex way, acting either as an oncogenic molecule or as a tumor suppressor (Sporn and Liby 2012; Kensler and Wakabavashi 2010).”
BackgroundEndocytosis of particulate matter induces cytokine production by neutrophil via Toll-like receptor 4
Miyake, T., Wang, D., Matsuoka, H., Morita, K., Yasuda, H., Yatera, K., Kanazawa, T., & Yoshida, Y. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.02.020 · Cited by 20
Liu, R.-J., Yu, X.-D., Yan, S.-S., Guo, Z., Zao, X., & Zhang, Y. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5651 · Cited by 21
“Nuclear factor erythroid 2‑related factor 2 (NRF2) has long been known to influence tumor progression as a pivotal regulator of the antioxidant response (135,136).”
BackgroundTang, W., Huang, X., Yi, Y.-D., Cao, F., Deng, M., Fan, J., Jiang, Z., Tao, L.-M., Wang, X., & Shi, L. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-03082-3 · Cited by 26
Saito, A., Ishikawa, S., Yang, K., Sawa, A., & Ishizuka, K. (2025) · Journal of Nutritional Science · doi:10.1017/jns.2025.10033 · Cited by 26
“A trial on advanced pancreatic cancer showed no impact on patients ’ overall function (41) , potentially due to Nrf2 ’ s dual role in cancer progression depending on genetic mutations (42) .”
p62 functions as a signal hub in metal carcinogenesis
Zhang, Z., & Costa, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.014 · Cited by 21
Tempeh extract reduces cellular ROS levels and upregulates the expression of antioxidant enzymes
Surya, R., Romulo, A., & Suryani, Y. (2021) · Food Research · doi:10.26656/fr.2017.5(3).560 · Cited by 26
“ROS may oxidize cysteine residues in Keap1, thus modifying its conformation and liberating Nrf2 to undergo gene expression (Sporn and Liby, 2012; Tonelli et al., 2018). eISSN: 2550-2166 © 2021 The Authors.”
BackgroundThe role of the Nrf2/GSH antioxidant system in cisplatin resistance in malignant rhabdoid tumours
Barroeta, P. H., O’Sullivan, M. J., & Zisterer, D. M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04734-x · Cited by 22
“Moreover, high Nrf2 expression has also been correlated with chemoresistant phenotype in several malignancies such as lung cancer and gallbladder cancer, as it can help cells overcome oxidative stress induced by anti-cancer drug treatment (Sporn and Liby 2012).”
BackgroundDuran, J. P., Luna, A., Portilla, A., Martínez, P., Ceballos, G. M., Ortíz-Flores, M., Solis‐Paredes, J. M., & Nájera, N. (2023) · Molecules · doi:10.3390/molecules28176229 · Cited by 21
“In this regard, it has been reported that Nfr2 has protective roles in suppressing oxidative or electrophilic stress and inhibiting carcinogenesis [31].”
BackgroundChen, F., Liu, H.-S., Yan, J.-X., Shi, Q., Yang, H., Cao, S., & Qi, X. (2024) · LWT · doi:10.1016/j.lwt.2024.117081 · Cited by 20
Genrich, G., Kruppa, M., Lenk, L., Helm, O., Broich, A., Freitag‐Wolf, S., Röcken, C., Sipos, B., Schäfer, H., & Sebens, S. (2016) · BMC Cancer · doi:10.1186/s12885-016-2191-7 · Cited by 20
Gonçalves, A. C., Alves, R., Baldeiras, I., Cortesão, E., Carda, J. P., Branco, C. C., Oliveiros, B., Loureiro, L., Pereira, A., Costa, N., et al. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22478 · Cited by 26
“In fact, mutations in theNFE2L2 andKEAP1 genes have been found in hepatocellular carcinoma [69,70], stomach [69], lung [71,72], and breast 142 GONÇALVES ET AL.”
BackgroundKanegan, M. J. V., Dunn, D., Kaltenbach, L. S., Shah, B. D., Dong, H., McCoy, D. D., Yang, P., Peng, J., Shen, L., Du, L., et al. (2016) · Scientific Reports · doi:10.1038/srep25626 · Cited by 21
Huang, B. K., Langford, T. F., & Sikes, H. D. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6482 · Cited by 20
“To provide a genetic basis for the increased resistance, we investigated the role of Nrf-2, a transcription factor that is a master regulator for many protective functions from oxidative stress inside the cell (8, 46).”
BackgroundPerioperative stroke as a predictor of mortality and morbidity in patients undergoing CABG
Mehta, A. M., Gleason, T. G., Wechsler, L. R., Winger, D. G., Wang, L., & Thirumala, P. D. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.06.035 · Cited by 20
Kitazawa, M., Hatta, T., Sasaki, Y., Fukui, K., Ogawa, K., Fukuda, E., Goshima, N., Okita, N. T., Yamada, Y., Nakagama, H., et al. (2020) · Cancer Science · doi:10.1111/cas.14275 · Cited by 22
Liu, Y. J., Houldsworth, J., Emmadi, R., Dyer, L. M., & Wolff, D. J. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.04.004 · Cited by 19
The potential roles of Nrf2/Keap1 signaling in anticancer drug interactions
Wang, J., Jin, Y., Cao, M., Zhao, Z., Cao, B., & Yu, S. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100028 · Cited by 23
“initiation and progression of cancer, and has been implied in both the resistance to and the toxicities of anticancer drugs (Rojo de la Vega et al., 2018; Sporn and Liby, 2012).”
BackgroundLung cancer chemoprevention: difficulties, promise and potential agents?
Dragnev, K., You, M., Wang, Y., & Lubet, R. A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.731392 · Cited by 20
“Groups of synthetic olefinic triterpenoids developed by Sporn and colleagues have gained the most attention (Figure 1) [55].”
BackgroundInfluentialFang, K., Chu, Y., Zhao, Z., Li, Q., Li, H., Chen, T., & Xu, M. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.39557 · Cited by 22
“According to recent studies, NRF2 and ATF4 are critical effectors during nutrient deprivation [1, 13, 14].”
ResultWu, Y., Lee, Y., Li, W., Hsu, W., Lin, H., Chang, L., Huang, A., Jhan, J., Wu, W., Li, C., et al. (2021) · Pathology International · doi:10.1111/pin.13101 · Cited by 19
Wu, X., Zhang, Q., Guo, Y., Zhang, H., Guo, X., You, Q., & Wang, L. (2022) · Antioxidants · doi:10.3390/antiox11040619 · Cited by 22
“Disruption of the Keap1/Nrf2 PPI has been identified as a promising approach for oxidative and inflammatory stress-mediated cancer and other chronic diseases [122,123].”
BackgroundHRD1 in human malignant neoplasms: Molecular mechanisms and novel therapeutic strategy for cancer
Karamali, N., Ebrahimnezhad, S., Moghadam, R. K., Daneshfar, N., & Rezaiemanesh, A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120620 · Cited by 20
Khan, A. U., Khan, A., Shal, B., Khan, S., Khan, M., Ahmad, R., & Riaz, M. (2023) · Phytotherapy Research · doi:10.1002/ptr.7755 · Cited by 21
“Various oxidative stresses, for example, reactive oxygen species (ROS), hydrogen peroxide (H2O2), superoxides, and nitrous oxides, pose cells with threat of genome alteration with constant exposure (Lau, Villeneuve, Sun, Wong, & Zhang, 2008; Sporn & Liby, 2012).”
BackgroundDesign, synthesis, and biological activity of second-generation synthetic oleanane triterpenoids
Fu, L., Lin, Q.-X., Onyango, E. O., Liby, K. T., Sporn, M. B., & Gribble, G. W. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob01420a · Cited by 19
Self-citationKarttunen, M., Choy, W., & Cino, E. A. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b03295 · Cited by 20
Bismeijer, T., Canisius, S., & Wessels, L. F. A. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006520 · Cited by 19
Braeuning, A., & Schwarz, M. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.06.013 · Cited by 20
Role of nitric oxide in the response to photooxidative stress in prostate cancer cells
D’Este, F., Pietra, E. D., Pazmay, G. V. B., Xodo, L. E., & Rapozzi, V. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114205 · Cited by 20
O'Cathail, S. M., Wu, C., Thomas, R. J., Hawkins, M., Maughan, T., & Lewis, A. (2021) · Antioxidants · doi:10.3390/antiox10091380 · Cited by 22
“This allows NRF2 to function in an ‘oncogene’ fashion, promoting survival, resisting radiation and dysregulating metabolism [5,6].”
BackgroundThe dual role of ROS, antioxidants and autophagy in cancer
Walton, E. L. (2016) · Biomedical Journal · doi:10.1016/j.bj.2016.05.001 · Cited by 22
“Indeed, mouse embryonic fibroblasts expressing mutant G12V K-Ras have low levels of ROS [6], and in another model, high levels of antioxidant production through mechanisms such as the upregulation of Nrf2 offers a survival advantage [7].”
BackgroundWang, X.-M., She, C., Li, Q., Zhang, D., Xu, J., Li, M., Li, P., & Xu, H. (2020) · Aging · doi:10.18632/aging.103009 · Cited by 18
“Nrf2 post-transcriptional modification is one key mechanism for Nrf2 signaling cascade activation [28].”
BackgroundChoi, J., Kim, G. J., Kim, H. J., Nam, J., Kim, J., Chin, J., Park, J., Choi, H., & Park, K. D. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104434 · Cited by 18
Iseda, N., Itoh, S., Yoshizumi, T., Tomiyama, T., Morinaga, A., Yugawa, K., Shimokawa, M., Shimagaki, T., Wang, H., Kurihara, T., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1838 · Cited by 19
“(5) High expression of NRF2 is significantly associated with poor prognosis in various cancers,(6,7) and suppressing NRF2 led to”
BackgroundGuo, C. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.862791 · Cited by 19
Xie, T., Zahid, H., Ali, A. R., Joyce, R., Yang, G., Winz, C., Le, Y., Zhou, R., Furmanski, P., Hu, L., et al. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116375 · Cited by 21
Chêne, C., Rongvaux-Gaïda, D., Thomas, M., Rieger, F., Nicco, C., & Batteux, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1149869 · Cited by 19
Desai, J. K., Trangadia, B. J., Patel, U. D., Patel, H. B., Kalaria, V. A., & Kathiriya, J. B. (2023) · Environmental Pollution · doi:10.1016/j.envpol.2023.122206 · Cited by 19
Xia, L., Chen, Y., Li, J., Wang, J., Shen, K., Zhao, A., Jin, H., Zhang, G., Xi, Q., Xia, S., et al. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002772 · Cited by 21
“Previous studies showed that GSH synthesis could be controlled by Nrf2 through the activation of GSH metabolism-related enzymes.[28,29] Besides, Nrf2 has been proven to be related to cancer stemness in multiple ways, such as Nrf2-Keap1-Batch1 signaling pathway and CD133-Nrf2 axis.”
Backgroundda Costa, R. M., Dias, M. C., Alves, J. V., Silva, J. L. M., Rodrigues, D., da Silva, J. F., Francescato, H. D. C., Ramalho, L. N. Z., Coimbra, T. M., & Tostes, R. C. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115982 · Cited by 19
Pezacki, A. T., Gonciarz, R. L., Okamura, T., Matier, C. D., Torrente, L., Cheng, K., Miller, S. G., Ralle, M., Ward, N. P., DeNicola, G. M., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2401579121 · Cited by 18
Lee, K., Kim, S., Lee, Y., Lee, H., Lee, Y.-E., Park, H., Nahm, J. H., Ahn, S., Yu, S. J., Lee, K., et al. (2020) · Cancers · doi:10.3390/cancers12082128 · Cited by 20
“Activating NFE2L2 mutations and inactivating KEAP1 mutations were demonstrated to play important roles in tumor progression by preventing the degradation of nuclear factor E2-related factor2 (Nrf2), and the Nrf2/Keap1 pathway recently attracted attention as a potential therapeutic target for HCC [3,7,8].”
BackgroundOrrù, C., Perra, A., Kowalik, M. A., Rizzolio, S., Puliga, E., Cabras, L., Giordano, S., & Columbano, A. (2020) · Cancers · doi:10.3390/cancers12082305 · Cited by 19
NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer
O'Cathail, S. M., Wu, C., Lewis, A., Holmes, C. C., Hawkins, M., & Maughan, T. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.08.006 · Cited by 23
Messina, M. S., Torrente, L., Pezacki, A. T., Humpel, H. I., Li, E. L., Miller, S. G., Verdejo‐Torres, O., Padilla‐Benavides, T., Brady, D. C., Killilea, D. W., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2412816122 · Cited by 22
Natural and synthetic compounds for glioma treatment based on ROS-mediated strategy
Wang, Y., & Hu, J. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175537 · Cited by 18
S‑Glutathionylation and S‑Nitrosylation as Modulators of Redox-Dependent Processes in Cancer Cell
Kalinina, E. V., & Novichkova, M. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923070064 · Cited by 20
Serrano, J. J., & Medina, M. Á. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020498 · Cited by 18
“Table 1 summarizes the main metabolic and signaling pathways, enzymes and metabolites mentioned in this review.”
Targeting Oxidative Stress: A Novel Approach in Mitigating Cancer
Sil, P. C. (2015) · Biochemistry & Analytical Biochemistry · doi:10.4172/2161-1009.1000236 · Cited by 19
“To be very precise, it mainly regulates the intracellular production of glutathione (GSH) by interfering the expression of glutamate–cysteine ligase (GCL) complex and NADPH-generating enzymes [13].”
BackgroundROS release by PPARβ/δ-null fibroblasts reduces tumor load through epithelial antioxidant response
Tan, E. H. P., Sng, M. K., How, I. S. B., Chan, J. S. K., Chen, J., Tan, C. K., Wahli, W., & Tan, N. S. (2018) · Oncogene · doi:10.1038/s41388-017-0109-8 · Cited by 17
“It upregulates the expression of numerous antioxidant proteins to protect the cell from oxidative damages [34].”
BackgroundPianka, M.-L., Hesse, L., Deisinger, F., Sipos, B., Röcken, C., Arlt, A., Sebens, S., Helm, O., & Schäfer, H. (2018) · Oncogene · doi:10.1038/s41388-018-0518-3 · Cited by 19
Metadata
- Authors
- Sporn, M. B., & Liby, K. T.
- Affiliations
- Dartmouth College (US)
- Corresponding author
- Sporn, Michael B.
- Liby, Karen T.
- ORCID
- Liby, Karen T.
- Venue
- Nature Reviews Cancer
- Published
- 2012-07-19
- Volume
- 12
- Issue
- 8
- Pages
- 564-571
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3836441
- OpenAlex
- W2030749349
- Cited by
- 1,067
- References
- 120
- Citations by year
- 2026: 36 · 2025: 48 · 2024: 70 · 2023: 72 · 2022: 88 · 2021: 90 · 2020: 97 · 2019: 93 · 2018: 112 · 2017: 88 · 2016: 93 · 2015: 62 · 2014: 57 · 2013: 50 · 2012: 11
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA078814, P30CA023108)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Keywords
- Nrf2, chemoprevention, carcinogenesis, chemoresistance, transcription factor activation
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasms, Anticarcinogenic Agents, Tumor Suppressor Proteins, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.